Recombinant Sulfated HIV Envelope Protein and Methods for Making Protein

This technology comprises sulfated recombinant gp120 proteins and peptides. Also included are methods for producing sulfated recombinant gp120 proteins. The focus of this technology is on sulfation of two tyrosines in the V2 loop of the HIV major envelope glycoprotein, gp120, which increase the stability of gp120 and promote the synthesis of gp120 protein in its native "closed" conformation. Gp120 in its native form is highly sulfated; however, recombinant gp120 produced for vaccines or structural analyses typically display low levels of V2 tyrosine sulfation. Sulfation of the V2 loop results in increased binding to trimer-recognizing anti-HIV antibodies specific to the V2 loop region of gp120 (PG9, PG16, CH01, PGT145) and decreased binding of CD4. The sulfation of recombinant gp120 is accomplished by over expression of a tyrosyl sulfotransferase in the producing cell line. Preliminary experiments indicate the recombinant sulfated gp120 proteins can be used to elicit the formation of HIV neutralizing antibodies in immunized animals.

Potential Commercial Applications: Competitive Advantages:
  • Design of HIV vaccines
  • Production of HIV vaccines
  • Induction of Neutralizing Antibodies
  • HIV vaccine booster protein
  • Consistent sulfation/production of gp120
  • Gp120 vaccine component with improved stability and immunogenicity
  • Recombinant gp120 vaccine component in native conformation

Development Stage:
  • Early-stage
  • In vitro data available
  • In vivo data available (animal)
  • Prototype


Paolo Lusso (NIAID)  ➽ more inventions...

Raffaello Cimbro (NIAID)  ➽ more inventions...

Intellectual Property:
US Pat: 9,775,895 issued 2017-10-03
US Application No. 61/736,350 filed on 2012-12-12
PCT Application No. PCT/US2013/074801 filed on 2013-12-12
Related Technology: Unpublished modifications to recombinant GP120.

Cimbro R, et al. PMID 24569807

Collaboration Opportunity:

The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology as a HIV vaccine component or a therapeutic for treating HIV. For collaboration opportunities, please contact Bill Ronnenberg at or 301-451-3522.

Licensing Contact:
Christopher Kornak, J.D.
Phone: 240-627-3705

OTT Reference No: E-067-2012-0
Updated: Apr 15, 2014